Kim Jin-Wook, Inagaki Yuichi, Mitsutake Susumu, Maezawa Nobuhiro, Katsumura Shigeo, Ryu Yeon-Woo, Park Chang-Seo, Taniguchi Masaru, Igarashi Yasuyuki
Department of Biomembrane and Biofunctional Chemistry, Graduate School of Pharmaceutical Science, Hokkaido University, Kita 12, Nishi 6, Kita-ku, Sapporo 060-0812, Japan.
Biochim Biophys Acta. 2005 Dec 30;1738(1-3):82-90. doi: 10.1016/j.bbalip.2005.10.007. Epub 2005 Nov 14.
Antigen-induced degranulation of mast cells plays a pivotal role in allergic and inflammatory responses. Recently, ceramide kinase (CERK) and its phosphorylated product ceramide 1-phosphate (C1P) have emerged as important players in mast cell degranulation. Here, we describe the synthesis of a novel F-12509A olefin isomer, K1, as an effective CERK inhibitor. In vitro kinase assays demonstrated that K1 effectively inhibits CERK without inhibiting sphingosine kinase and diacylglycerol kinase. Treating RBL-2H3 cells with K1 reduced cellular C1P levels to 40% yet had no effect on cell growth. Furthermore, treatment with K1 significantly suppressed both calcium ionophore- and IgE/antigen-induced degranulation, indicating that K1 interferes with signals that happen downstream of Ca(2+) mobilization. Finally, we show that K1 affects neither IgE/antigen-induced global tyrosine phosphorylation nor subsequent Ca(2+) elevation, suggesting a specificity for CERK-mediated signals. Our novel CERK inhibitor provides a useful tool for studying the biological functions of CERK and C1P. Moreover, to our knowledge, this is the first report demonstrating that inhibition of CERK suppresses IgE/antigen-induced mast cell degranulation. This finding suggests that CERK inhibitors might be a potential therapeutic tool in the treatment of allergic diseases.
抗原诱导的肥大细胞脱颗粒在过敏和炎症反应中起关键作用。最近,神经酰胺激酶(CERK)及其磷酸化产物神经酰胺1-磷酸(C1P)已成为肥大细胞脱颗粒的重要参与者。在此,我们描述了一种新型F-12509A烯烃异构体K1的合成,它是一种有效的CERK抑制剂。体外激酶测定表明,K1能有效抑制CERK,而不抑制鞘氨醇激酶和二酰基甘油激酶。用K1处理RBL-2H3细胞可使细胞内C1P水平降至40%,但对细胞生长没有影响。此外,用K1处理可显著抑制钙离子载体和IgE/抗原诱导的脱颗粒,表明K1干扰了Ca(2+)动员下游发生的信号。最后,我们表明K1既不影响IgE/抗原诱导的整体酪氨酸磷酸化,也不影响随后的Ca(2+)升高,这表明其对CERK介导的信号具有特异性。我们的新型CERK抑制剂为研究CERK和C1P的生物学功能提供了一个有用的工具。此外,据我们所知,这是第一份证明抑制CERK可抑制IgE/抗原诱导的肥大细胞脱颗粒的报告。这一发现表明,CERK抑制剂可能是治疗过敏性疾病的一种潜在治疗工具。